-
1
المؤلفون: Patrick R. Lawler, Rob Fowler, Edward Litton, Colin McArthur, Katrina Orr, Ryan Zarychanski, Christopher W. Seymour, Richard Beasley, Herman Goossens, Timothy D. Girard, John C. Marshall, Rachael Parke, Marc J. M. Bonten, Susan C. Morpeth, Lennie P. G. Derde, Abi Beane, Steven Y. C. Tong, Alisa Higgins, Asad E. Patanwala, Jane C. Parker, Anna McGlothlin, Menno de Jong, Shay McGuinness, Stephanie K. Montgomery, Alistair Nichol, Frank L. van de Veerdonk, Zahra Bhimani, Christopher M. Horvat, Allen C. Cheng, Manu Shankar-Hari, Anthony C. Gordon, Ewan C. Goligher, Farah Al Beidh, Lise J Estcourt, Kelsey Linstrum, Salim Malakouti, Andrew J King, Michelle A. Detry, Bryan J. McVerry, Francois Lamontagne, Rashan Haniffa, Alexis F. Turgeon, Srinivas Murthy, Cameron Green, Yaseen M. Arabi, Paul R Mouncey, Lolowa Al Swaidan, Eamon Duffy, Lindsay R. Berry, Roger J. Lewis, Scott M. Berry, Kathryn M Rowan, Djillali Annane, Christina Saunders, Meredith Buxton, Mark Fitzgerald, Anne Turner, Elizabeth Lorenzi, Adrian Buzgau, Derek C. Angus, David T. Huang, Charlotte Bradbury, Steven A R Webb, Marlene Santos, Daniel F. McAuley, Thomas Hills, Frank M. Brunkhorst
المساهمون: REMAP-CAP Investigators, NIHR, National Institute for Health Research, AII - Infectious diseases, Vascular Medicine, ACS - Pulmonary hypertension & thrombosis, ARD - Amsterdam Reproduction and Development, Center of Experimental and Molecular Medicine, Infectious diseases
المصدر: Intensive care medicine
Intensive Care Medicine, 47, 8, pp. 867-886
Investigators, REMAP-CAP & Dark, P 2021, ' Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. ', Intensive care medicine, vol. 47, no. 8, pp. 867-886 . https://doi.org/10.1007/s00134-021-06448-5
2021, ' Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19 : REMAP-CAP randomized controlled trial ', Intensive Care Medicine, vol. 47, no. 8, pp. 867-886 . https://doi.org/10.1007/s00134-021-06448-5
Intensive care medicine, vol 47, iss 8
Arabi, Y M 2021, ' Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19 : REMAP-CAP randomized controlled trial ', Intensive Care Medicine, vol. 47, no. 8, pp. 867-886 . https://doi.org/10.1007/s00134-021-06448-5
Intensive Care Medicine, 47, 867-886
Intensive care medicine, 47(8), 867-886. Springer Verlag
INTENSIVE CARE MEDICINE
Intensive Care Medicineمصطلحات موضوعية: Comparative Effectiveness Research, Original, lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4], Lopinavir/ritonavir, Critical Care and Intensive Care Medicine, Lopinavir, law.invention, Randomized controlled trial, law, immune system diseases, Clinical endpoint, Medicine, CHLOROQUINE, Antiviral Agents/therapeutic use, virus diseases, Covid19, Adaptive platform trial, COVID-19, Hydroxychloroquine, Intensive care, Lopinavir-ritonavir, Pandemic, Pneumonia, Drug Combinations, Hydroxychloroquine/therapeutic use, Public Health and Health Services, Life Sciences & Biomedicine, medicine.drug, Adult, medicine.medical_specialty, Combination therapy, Ritonavir/therapeutic use, Critical Illness, Clinical Trials and Supportive Activities, Clinical Sciences, Antiviral Agents, COVID-19/drug therapy, 1117 Public Health and Health Services, LOPINAVIR/RITONAVIR, Critical Care Medicine, Clinical Research, General & Internal Medicine, Internal medicine, Humans, Lopinavir/therapeutic use, Science & Technology, Ritonavir, business.industry, SARS-CoV-2, 1103 Clinical Sciences, Bayes Theorem, Odds ratio, Emergency & Critical Care Medicine, COVID-19 Drug Treatment, Coronavirus, Good Health and Well Being, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Human medicine, REMAP-CAP Investigators, business
وصف الملف: application/vnd.openxmlformats-officedocument.wordprocessingml.document; application/pdf